Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 105, Issue 2, Pages 363-375Publisher
WILEY
DOI: 10.1002/cpt.1017
Keywords
-
Categories
Funding
- Bristol-Myers Squibb (BMS)
Ask authors/readers for more resources
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
